Daniel O. Persky, MD

-
Professor, Medicine
Associate Director, Clinical Investigations
Biography
Dr. Persky serves as a Professor of Medicine at the University of Arizona College of Medicine. He is currently the Associate Director of Clinical Investigations and Director, Clinical Trial Office - Tucson. He specializes in Hematology/Oncology, particularly in lymphoid malignancies, such as lymphoma and CLL.
Dr. Persky received his Bachelor’s Degree from Harvard University and his medical degree from the Albert Einstein College of Medicine in New York. He completed his internship and residency at the Mayo Graduate School of Medicine in Rochester, Minnesota, then returned to New York to complete a three-year fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center.
Cancer Focus
Clinical translational research in lymphoid malignancies (lymphomas and CLL).
Selected Publications
Persky, D. O., "Limited-stage DLBCL: it's patient selection.", Blood, vol. 131, issue 2, pp. 155-156, 2018 01 11. PMCID: PMC5757692 PMID: 29326347
Kelly, K. R., J. W. Friedberg, S. I. Park, K. McDonagh, J. Hayslip, D. Persky, J. Ruan, S. Puvvada, P. Rosen, S. Padmanabha Iyer, et al., "Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.", Clin Cancer Res, vol. 24, issue 24, pp. 6150-6159, 2018 Dec 15. PMID: 30082475
Persky, D. O., H. Li, L. M. Rimsza, P. M. Barr, L. L. Popplewell, C. L. Bane, A. Von Gehr, M. LeBlanc, R. I. Fisher, S. M. Smith, et al., "A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.", Am J Hematol, vol. 93, issue 4, pp. 486-493, 2018 Aug. PMCID: PMC5842116 PMID: 29266344
Puvvada, S. D., J. M. Guillén-Rodríguez, X. I. Rivera, K. Heard, L. Inclan, M. Schmelz, J. H. Schatz, and D. O. Persky, "A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma.", Oncology, vol. 93, issue 6, pp. 401-405, 2017. PMID: 28869931
Kendrick, S., L. M. Rimsza, D. W. Scott, G. W. Slack, P. Farinha, K. L. Tan, D. Persky, S. Puvvada, J. M. Connors, L. Sehn, et al., "Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.", Virchows Arch, vol. 470, issue 1, pp. 113-117, 2017 Jan. PMID: 27888357
Puvvada, S. D., H. Li, L. M. Rimsza, S. H. Bernstein, R. I. Fisher, M. LeBlanc, M. Schmelz, B. Glinsmann-Gibson, T. P. Miller, A-M. Maddox, et al., "A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.", Leuk Lymphoma, vol. 57, issue 10, pp. 2359-69, 2016 10. PMCID: PMC5140034 PMID: 26758422
Persky, D. O., T. P. Miller, J. M. Unger, C. M. Spier, S. Puvvada, D. B Stea, O. W. Press, L. S. Constine, K. P. Barton, J. W. Friedberg, et al., "Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.", Blood, vol. 125, issue 2, pp. 236-41, 2015 Jan 08. PMCID: PMC4287635 PMID: 25395425
Persky, D. O., J. M. Unger, C. M. Spier, B. Stea, M. LeBlanc, M. J. McCarty, L. M. Rimsza, R. I. Fisher, and T. P. Miller, "Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.", J Clin Oncol, vol. 26, issue 14, pp. 2258-63, 2008 May 10. PMID: 18413640